Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment

Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critic...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care Vol. 38; no. 6; pp. 1161 - 1172
Main Authors Van Gaal, Luc, Scheen, André
Format Journal Article Web Resource
LanguageEnglish
Published United States American Diabetes Association 01.06.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed.
AbstractList Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed.
Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered. However, many traditional glucose-lowering medications may lead to weight gain. This article focuses on the potential of currently available pharmacological strategies and on emerging approaches in development to support the glycemic and weight-loss goals of individuals with type 2 diabetes. Two pharmacotherapy types are considered: those developed primarily for blood glucose control that have a favorable effect on body weight and those developed primarily to induce weight loss that have a favorable effect on blood glucose control. Finally, the potential of combination therapies for the management of obese patients with type 2 diabetes is discussed. 111 references
Author Scheen, André
Van Gaal, Luc
Author_xml – sequence: 1
  givenname: Luc
  surname: Van Gaal
  fullname: Van Gaal, Luc
  organization: Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium
– sequence: 2
  givenname: André
  surname: Scheen
  fullname: Scheen, André
  organization: Department of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, University of Liège, Liège, Belgium
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25998297$$D View this record in MEDLINE/PubMed
BookMark eNptkU1v1DAQhi1URLeFA38AWeJCD6H-SmJzq5aWIhUhoUUcrUk8SV0lzmI7SP33TbQth6qnGc0872hm3hNyFKaAhLzn7LOQsj53LVcFryR7RTbcyLIoS6WPyIZxZYrSGHFMTlK6Y4wppfUbciyWoham3pBff9D3t5n-gAA9jhgy9YHu7vdIBf3qocGM6QvdzjGuPQiOXo4Yex96erHfxwnaW0w0T3QXEfI64C153cGQ8N1jPCW_ry532-vi5ue379uLmwJUbXJRgzCKQwWdaZVrRNd0AmvdtshkCU52QtYOpO601KKSypWlhNqgcLwGVzp5SuRh7uCxRzvFxtt_wk7gD_k89BZa26AVotKWayE5W1SfDqpl978zpmxHn1ocBgg4zcnymolKqYqVC_rxGXo3zTEsN1le6UpzaVi1UB8eqbkZ0dl99CPEe_v04wU4OwBtnFKK2P1HOLOrf3b1z67-Lez5M7b1GbKfQo7ghxcUD1tQmi8
CODEN DICAD2
CitedBy_id crossref_primary_10_1016_S2213_8587_17_30092_X
crossref_primary_10_1097_01_NUMA_0000491124_22612_0e
crossref_primary_10_1080_14656566_2020_1729123
crossref_primary_10_1080_17425255_2018_1418325
crossref_primary_10_1016_j_jad_2021_11_020
crossref_primary_10_1111_dom_12657
crossref_primary_10_1111_dom_12932
crossref_primary_10_2337_dc22_S008
crossref_primary_10_1111_jdi_12810
crossref_primary_10_3390_nu14204325
crossref_primary_10_1038_nutd_2017_32
crossref_primary_10_1038_s41574_018_0118_x
crossref_primary_10_5812_ircmj_64581
crossref_primary_10_1016_j_diabres_2022_109900
crossref_primary_10_1016_j_jaim_2023_100768
crossref_primary_10_1016_j_med_2016_09_010
crossref_primary_10_1007_s00125_019_05065_8
crossref_primary_10_2337_dc23_S008
crossref_primary_10_1159_000480525
crossref_primary_10_3389_fendo_2017_00381
crossref_primary_10_3390_nu14183784
crossref_primary_10_2337_dc20_S008
crossref_primary_10_1186_s13643_020_01467_7
crossref_primary_10_1007_s11892_019_1236_0
crossref_primary_10_3389_fendo_2018_00634
crossref_primary_10_1007_s40265_017_0783_4
crossref_primary_10_1002_jssc_201600924
crossref_primary_10_1007_s40618_017_0719_6
crossref_primary_10_1111_jdi_12800
crossref_primary_10_1016_j_jcjd_2019_06_004
crossref_primary_10_1111_dom_12660
crossref_primary_10_3389_fcdhc_2022_1044005
crossref_primary_10_2215_CJN_07670715
crossref_primary_10_3390_nu14112299
crossref_primary_10_1016_j_cnur_2021_07_008
crossref_primary_10_1016_j_pec_2020_05_015
crossref_primary_10_1016_j_fochx_2022_100222
crossref_primary_10_1007_s12020_020_02396_0
crossref_primary_10_1055_a_2078_9491
crossref_primary_10_1007_s13300_024_01615_5
crossref_primary_10_3390_nu12092749
crossref_primary_10_1080_17512433_2017_1376652
crossref_primary_10_7762_cnr_2015_4_3_201
crossref_primary_10_1186_s12933_020_0990_2
crossref_primary_10_3389_fendo_2022_1094954
crossref_primary_10_1016_j_numecd_2023_05_024
crossref_primary_10_1161_CIR_0000000000000766
crossref_primary_10_1016_j_dsx_2016_12_026
crossref_primary_10_2337_dc18_1667
crossref_primary_10_1016_j_metabol_2019_03_007
crossref_primary_10_1016_j_pcd_2021_09_005
crossref_primary_10_4103_ym_ym_57_24
crossref_primary_10_1111_jdi_13125
crossref_primary_10_1038_nrendo_2016_86
crossref_primary_10_1038_s41574_018_0002_8
crossref_primary_10_1002_oby_21700
crossref_primary_10_1016_j_nursi_2016_11_008
crossref_primary_10_4158_EP_2018_0444
crossref_primary_10_1177_2165079920986160
crossref_primary_10_1080_00325481_2016_1169894
crossref_primary_10_1007_s40265_017_0801_6
crossref_primary_10_37376_jsh_vi71_5728
crossref_primary_10_1016_j_pcd_2022_02_002
crossref_primary_10_2337_dc22_2170
crossref_primary_10_1155_2018_1682959
crossref_primary_10_1186_s44263_024_00095_w
crossref_primary_10_23736_S2724_6507_23_04103_9
crossref_primary_10_58931_cdet_2023_115
crossref_primary_10_1080_2331205X_2019_1639880
crossref_primary_10_3390_ijms25031882
crossref_primary_10_1111_dom_16201
crossref_primary_10_1007_s10068_017_0223_y
crossref_primary_10_1111_dom_13573
crossref_primary_10_1111_bjd_17741
crossref_primary_10_2337_dcS15_3016
crossref_primary_10_1097_01_NURSE_0000480595_99521_56
crossref_primary_10_1186_s12937_023_00909_x
crossref_primary_10_1016_j_numecd_2016_11_124
crossref_primary_10_3390_microorganisms8081246
crossref_primary_10_1177_0884533617713189
crossref_primary_10_1016_j_lfs_2022_120543
crossref_primary_10_1016_j_biopha_2023_114582
crossref_primary_10_1016_j_pcd_2020_05_004
crossref_primary_10_5322_JESI_2020_29_4_351
crossref_primary_10_1080_13696998_2024_2316400
crossref_primary_10_1016_j_deman_2021_100005
crossref_primary_10_18553_jmcp_2019_18321
crossref_primary_10_24927_rce2024_006
crossref_primary_10_1007_s13300_019_0645_z
crossref_primary_10_1080_14656566_2017_1297424
crossref_primary_10_1007_s13300_023_01511_4
crossref_primary_10_1002_oby_21883
crossref_primary_10_2147_VHRM_S345810
crossref_primary_10_1093_bjsopen_zrad077
crossref_primary_10_1136_bmjdrc_2021_002136
crossref_primary_10_3111_13696998_2015_1069297
crossref_primary_10_1007_s13679_020_00419_5
crossref_primary_10_3390_ijms23158365
crossref_primary_10_1016_j_nutres_2018_05_005
crossref_primary_10_1080_00325481_2016_1210988
crossref_primary_10_1097_MD_0000000000003462
crossref_primary_10_1007_s11892_016_0789_4
crossref_primary_10_1186_s13063_021_05442_y
crossref_primary_10_1007_s13300_017_0343_7
crossref_primary_10_3390_fermentation9030254
crossref_primary_10_1007_s40265_020_01393_x
crossref_primary_10_1038_s41366_022_01217_w
crossref_primary_10_15406_mojddt_2017_01_00005
crossref_primary_10_2337_dc25_S008
crossref_primary_10_1002_dmrr_3099
crossref_primary_10_2337_ds17_0045
crossref_primary_10_1007_s11695_020_05075_1
crossref_primary_10_12968_npre_2017_15_7_338
crossref_primary_10_1016_j_mmm_2021_10_012
crossref_primary_10_1080_13543784_2016_1221925
crossref_primary_10_1016_j_clinthera_2017_03_013
crossref_primary_10_1093_cdn_nzz067
crossref_primary_10_1016_j_jdiacomp_2017_06_004
crossref_primary_10_1155_2018_9264204
crossref_primary_10_36290_vnl_2020_128
crossref_primary_10_1371_journal_pone_0282143
crossref_primary_10_2337_dc15_0875
crossref_primary_10_1586_17512433_2016_1141046
crossref_primary_10_1155_2020_9327910
crossref_primary_10_1177_1934578X241259377
crossref_primary_10_2174_011871529X326042241031060350
crossref_primary_10_1007_s11892_017_0894_z
crossref_primary_10_1016_j_clinthera_2019_01_001
crossref_primary_10_3803_EnM_2019_34_3_247
crossref_primary_10_1186_s13098_019_0400_7
crossref_primary_10_1177_2047487317709369
crossref_primary_10_1080_10408398_2021_1873732
crossref_primary_10_2337_dc18_2270
crossref_primary_10_1186_s12889_020_09231_1
crossref_primary_10_1016_j_diabres_2016_04_033
crossref_primary_10_1371_journal_pone_0292553
crossref_primary_10_4163_jnh_2023_56_1_24
crossref_primary_10_3390_nu15173693
crossref_primary_10_3390_nu16020329
crossref_primary_10_1016_S1957_2557_18_30043_9
crossref_primary_10_1016_j_jaim_2017_03_005
crossref_primary_10_1016_j_ejphar_2016_11_028
crossref_primary_10_1111_dom_14745
crossref_primary_10_1111_dom_13658
crossref_primary_10_2174_1573399814666180403164529
crossref_primary_10_1517_14740338_2015_1100167
crossref_primary_10_1007_s13669_015_0129_8
crossref_primary_10_1016_j_tvir_2020_100654
crossref_primary_10_1111_dom_14221
crossref_primary_10_2337_dc21_S008
crossref_primary_10_1002_dmrr_2981
crossref_primary_10_1038_nrendo_2016_51
crossref_primary_10_2337_dc24_S008
crossref_primary_10_1007_s11684_021_0873_2
crossref_primary_10_1136_bmjopen_2020_038970
crossref_primary_10_1093_advances_nmz002
crossref_primary_10_1097_NHH_0000000000000576
crossref_primary_10_1007_s13340_018_0345_3
crossref_primary_10_3390_ijms25042324
Cites_doi 10.2337/diacare.22.7.1137
10.2337/dc14-2441
10.1002/oby.20356
10.1177/2040622313506730
10.2337/db13-0710
10.1152/ajpregu.00495.2013
10.1038/oby.2012.59
10.1111/j.1463-1326.2009.01059.x
10.1056/NEJMoa012512
10.1002/oby.20662
10.1016/S0140-6736(13)62154-6
10.1111/j.1464-5491.2004.01474.x
10.2337/dc11-0931
10.1002/dmrr.2479
10.1001/archinternmed.2009.266
10.1002/oby.20663
10.1001/jama.2012.9931
10.2337/dc13-0234
10.1007/BF02576216
10.1016/S0140-6736(11)60205-5
10.1210/jcem.87.6.8567
10.1007/s40265-014-0337-y
10.1111/dom.12083
10.3945/ajcn.2009.28449B
10.1016/0167-4889(94)00237-9
10.1038/nrendo.2013.113
10.1016/j.diabet.2007.01.003
10.1007/s00592-013-0489-3
10.3109/07853890.2010.541490
10.2337/diabetes.50.1.105
10.1056/NEJMra041001
10.1097/MED.0b013e32835edb32
10.1038/sj.ijo.0802783
10.1016/j.amjcard.2005.03.053
10.2337/diacare.28.6.1526
10.2337/dc13-2338
10.2337/diacare.11.7.567
10.1111/dom.12054
10.1093/ajhp/62.2.173
10.2337/dc12-2462
10.2337/dc12-1391
10.1093/eurpub/ckl262
10.1517/14712598.2011.619974
10.2337/dc13-1928
10.1111/j.1365-2710.2011.01280.x
10.1111/j.1742-1241.2009.02265.x
10.2165/00002018-200730120-00005
10.1111/j.1463-1326.2009.01075.x
10.2174/1389201015666140915150312
10.7326/0003-4819-154-2-201101180-00300
10.1186/1471-2458-9-88
10.1016/S0140-6736(09)60659-0
10.1056/NEJMp1314078
10.1186/1472-6823-13-58
10.1111/j.1463-1326.2012.01556.x
10.1586/eem.12.51
10.1038/282503a0
10.1159/000103273
10.1152/ajpregu.00755.2010
10.3810/pgm.2014.05.2753
10.1016/S0140-6736(02)07952-7
10.1016/S2213-8587(14)70004-X
10.1210/jcem.82.12.4460
10.1111/j.1742-1241.2012.03006.x
10.1111/j.1463-1326.2009.01158.x
10.1007/s001250051172
10.1016/S0140-6736(09)61375-1
10.1111/dom.12307
10.1111/j.1463-1326.2010.01337.x
10.1097/MED.0b013e328357f0e0
10.2337/dc10-2415
10.1111/j.1463-1326.2008.00970.x
10.3945/ajcn.111.024927
10.1038/nm.3761
10.1210/jc.2011-2260
10.2174/187221411797265917
10.1185/03007995.2012.684044
10.1056/NEJMoa1105816
10.2337/dc09-1203
10.1242/dmm.009621
10.1111/dom.12189
10.2337/diacare.27.1.155
10.1185/03007995.2013.850066
10.2337/db13-1609
10.1038/nchembio.209
10.1056/NEJMoa0909809
10.1517/14656566.2011.581663
10.1038/oby.2012.66
10.1111/j.1463-1326.2006.00686.x
10.1038/ijo.2011.158
10.1016/S0140-6736(98)07019-6
10.2337/dc06-2001
10.1111/dom.12048
10.1007/s00125-011-2332-0
10.1038/nrendo.2009.48
10.1185/03007995.2011.590127
10.1038/nature05487
10.1369/jhc.2008.951319
10.2337/dc14-0930
10.1111/j.1463-1326.2012.01673.x
10.1111/j.1742-1241.2006.01128.x
ContentType Journal Article
Web Resource
Copyright 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Copyright American Diabetes Association Jun 2015
Copyright_xml – notice: 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
– notice: Copyright American Diabetes Association Jun 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
ASE
FPQ
K6X
Q33
DOI 10.2337/dc14-1630
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
British Nursing Index
British Nursing Index (BNI) (1985 to Present)
British Nursing Index
Université de Liège - Open Repository and Bibliography (ORBI)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
British Nursing Index
DatabaseTitleList MEDLINE
British Nursing Index

ProQuest Health & Medical Complete (Alumni)
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1935-5548
EndPage 1172
ExternalDocumentID oai_orbi_ulg_ac_be_2268_182310
3708747661
25998297
10_2337_dc14_1630
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
Feature
GroupedDBID ---
-ET
..I
.XZ
08P
0R~
18M
29F
2WC
4.4
53G
5GY
5RE
5RS
5VS
6PF
8R4
8R5
AAFWJ
AAIKC
AAKAS
AAMNW
AAWTL
AAYEP
AAYXX
ABOCM
ABPPZ
ACGFO
ACGOD
ADBBV
ADZCM
AEGXH
AENEX
AERZD
AFOSN
AFRAH
AHMBA
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EDB
EJD
EMOBN
EX3
F5P
GX1
H13
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
KQ8
L7B
M0K
M5~
O5R
O5S
O9-
OK1
OVD
P2P
PCD
Q2X
RHI
SV3
TDI
TEORI
TR2
TWZ
VVN
W8F
WH7
WOQ
WOW
YHG
YOC
~KM
.55
.GJ
3O-
41~
7RV
7X2
7X7
88E
88I
8AF
8AO
8C1
8F7
8FE
8FH
8FI
8FJ
8G5
AAQOH
AAQQT
AAYJJ
ABUWG
AFFNX
AFKRA
AI.
AN0
AQUVI
ATCPS
AZQEC
BCR
BCU
BEC
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BVXVI
C1A
CCPQU
CGR
CUY
CVF
DWQXO
ECM
EIF
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
IAG
ITC
J5H
K9-
M0R
M0T
M1P
M2O
M2P
M2Q
N4W
NAPCQ
NPM
PEA
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
S0X
SJFOW
UKHRP
VH1
WHG
X7M
ZCG
ZGI
ZXP
K9.
ASE
FPQ
K6X
Q33
ID FETCH-LOGICAL-a479t-7a2941a6af9c4db2fbf2e78cce035ad3f237da38f8382634d553a79e2d17ad5d3
ISSN 0149-5992
1935-5548
IngestDate Fri Jul 25 15:26:15 EDT 2025
Fri Jul 11 10:03:45 EDT 2025
Mon Jun 30 16:58:02 EDT 2025
Mon Jul 21 05:53:57 EDT 2025
Thu Apr 24 22:57:08 EDT 2025
Tue Jul 01 04:11:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a479t-7a2941a6af9c4db2fbf2e78cce035ad3f237da38f8382634d553a79e2d17ad5d3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
content type line 23
scopus-id:2-s2.0-84940559645
PMID 25998297
PQID 1686813906
PQPubID 47715
PageCount 12
ParticipantIDs liege_orbi_v2_oai_orbi_ulg_ac_be_2268_182310
proquest_miscellaneous_1702644605
proquest_journals_1686813906
pubmed_primary_25998297
crossref_primary_10_2337_dc14_1630
crossref_citationtrail_10_2337_dc14_1630
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-06-01
PublicationDateYYYYMMDD 2015-06-01
PublicationDate_xml – month: 06
  year: 2015
  text: 2015-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Alexandria
PublicationTitle Diabetes care
PublicationTitleAlternate Diabetes Care
PublicationYear 2015
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
References Wing (2022031301280987800_B7) 2010; 170
Göke (2022031301280987800_B36) 1993; 193
Fadini (2022031301280987800_B49) 2013; 50
Wilding (2022031301280987800_B34) 2006; 60
Kahn (2022031301280987800_B105) 2014; 383
Rueda-Clausen (2022031301280987800_B78) 2013; 9
Ferrannini (2022031301280987800_B64) 2014; 57
Toft-Nielsen (2022031301280987800_B40) 1999; 22
Devenny (2022031301280987800_B63) 2012; 20
2022031301280987800_B3
Egan (2022031301280987800_B54) 2014; 370
Day (2022031301280987800_B109) 2009; 5
Van Gaal (2022031301280987800_B2) 2006; 444
Wing (2022031301280987800_B8) 2011; 34
Rosenstock (2022031301280987800_B82) 2007; 30
Buse (2022031301280987800_B48) 2009; 374
Guh (2022031301280987800_B4) 2009; 9
Kolterman (2022031301280987800_B41) 2005; 62
Cabrera (2022031301280987800_B15) 2012; 28
Zander (2022031301280987800_B38) 2002; 359
Samson (2022031301280987800_B53) 2013; 20
Dushay (2022031301280987800_B44) 2012; 35
2022031301280987800_B45
O’Neil (2022031301280987800_B71) 2012; 20
Katsiki (2022031301280987800_B86) 2011; 43
Liebl (2022031301280987800_B26) 2009; 11
Sumithran (2022031301280987800_B20) 2011; 365
Kliewer (2022031301280987800_B107) 2010; 91
Jendle (2022031301280987800_B89) 2009; 11
Gadde (2022031301280987800_B80) 2011; 377
Knowler (2022031301280987800_B6) 2002; 346
Jacob (2022031301280987800_B77) 2009; 11
Cummings (2022031301280987800_B97) 2013; 15
Younk (2022031301280987800_B68) 2011; 12
Liakos (2022031301280987800_B67) 2014; 16
Woods (2022031301280987800_B27) 1979; 282
Rosenbaum (2022031301280987800_B22) 2008; 118
Tornehave (2022031301280987800_B37) 2008; 56
Pi-Sunyer (2022031301280987800_B12) 2005; 28
Bolinder (2022031301280987800_B58) 2014; 16
2022031301280987800_B103
Rubin (2022031301280987800_B9) 2014; 37
Russell-Jones (2022031301280987800_B25) 2007; 9
Clemmensen (2022031301280987800_B102) 2014; 63
Toft (2022031301280987800_B17) 2007; 17
Maclean (2022031301280987800_B19) 2011; 301
Hiatt (2022031301280987800_B90) 2012; 308
Blonde (2022031301280987800_B51) 2009; 11
Cai (2022031301280987800_B28) 2001; 50
Lovshin (2022031301280987800_B98) 2009; 5
Rodgers (2022031301280987800_B74) 2012; 5
Singh-Franco (2022031301280987800_B69) 2011; 13
Berne (2022031301280987800_B70) 2005; 22
Grasso (2022031301280987800_B99) 2011; 5
Esposito (2022031301280987800_B43) 2011; 27
Niswender (2022031301280987800_B47) 2013; 15
Tatarkiewicz (2022031301280987800_B42) 2014; 306
UK Prospective Diabetes Study (UKPDS) Group (2022031301280987800_B13) 1998; 352
De Block (2022031301280987800_B46) 2012; 7
van Dieren (2022031301280987800_B24) 2012; 14
Riddle (2022031301280987800_B96) 2013; 36
de Luis (2022031301280987800_B21) 2007; 51
Buse (2022031301280987800_B94) 2011; 154
Van Gaal (2022031301280987800_B1) 2012; 19
Hermansen (2022031301280987800_B32) 2007; 30
Inzucchi (2022031301280987800_B5) 2015; 38
Pencek (2022031301280987800_B52) 2012; 66
Berhan (2022031301280987800_B66) 2013; 13
Wilding (2022031301280987800_B81) 2004; 28
Foster (2022031301280987800_B10) 2009; 169
Yki-Järvinen (2022031301280987800_B29) 1997; 82
Bays (2022031301280987800_B61) 2014; 22
Hollander (2022031301280987800_B73) 2013; 36
Hughes (2022031301280987800_B110) 2013; 21
Astrup (2022031301280987800_B88) 2012; 36
Omar (2022031301280987800_B108) 2014; 63
Garvey (2022031301280987800_B72) 2014; 37
Garvey (2022031301280987800_B84) 2012; 95
Scheen (2022031301280987800_B55) 2015; 75
Bolinder (2022031301280987800_B57) 2012; 97
Buse (2022031301280987800_B95) 2013; 62
Mäkimattila (2022031301280987800_B31) 1999; 42
Stenlöf (2022031301280987800_B59) 2013; 15
Scheen (2022031301280987800_B16) 2007; 33
Fonseca (2022031301280987800_B14) 2013; 36
Eriksson (2022031301280987800_B30) 1995; 1266
Perkins (2022031301280987800_B65) 2014; 37
Tam (2022031301280987800_B101) 2011; 11
Willms (2022031301280987800_B39) 1996; 81
Derosa (2022031301280987800_B75) 2012; 37
Rosenstock (2022031301280987800_B92) 2010; 33
2022031301280987800_B85
Miyazaki (2022031301280987800_B35) 2002; 87
Tonstad (2022031301280987800_B83) 2005; 96
Moon (2022031301280987800_B100) 2012; 55
Araujo (2022031301280987800_B93) 2014; 15
Torgerson (2022031301280987800_B76) 2004; 27
Smith (2022031301280987800_B79) 2010; 363
Yki-Järvinen (2022031301280987800_B33) 2004; 351
Scheen (2022031301280987800_B23) 2014; 2
Gallwitz (2022031301280987800_B50) 2010; 64
2022031301280987800_B91
Stenlöf (2022031301280987800_B60) 2014; 30
Look AHEAD Research Group (2022031301280987800_B11) 2014; 22
The DCCT Research Group (2022031301280987800_B18) 1988; 11
Usiskin (2022031301280987800_B62) 2014; 126
Astrup (2022031301280987800_B87) 2009; 374
Finan (2022031301280987800_B104) 2015; 21
Meneghini (2022031301280987800_B111) 2013; 15
Zhang (2022031301280987800_B56) 2014; 30
Troke (2022031301280987800_B106) 2014; 5
References_xml – volume: 22
  start-page: 1137
  year: 1999
  ident: 2022031301280987800_B40
  article-title: Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
  publication-title: Diabetes Care
  doi: 10.2337/diacare.22.7.1137
– volume: 38
  start-page: 140
  year: 2015
  ident: 2022031301280987800_B5
  article-title: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc14-2441
– volume: 21
  start-page: 1782
  year: 2013
  ident: 2022031301280987800_B110
  article-title: Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20356
– volume: 5
  start-page: 4
  year: 2014
  ident: 2022031301280987800_B106
  article-title: The future role of gut hormones in the treatment of obesity
  publication-title: Ther Adv Chronic Dis
  doi: 10.1177/2040622313506730
– volume: 63
  start-page: 101
  year: 2014
  ident: 2022031301280987800_B108
  article-title: Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice
  publication-title: Diabetes
  doi: 10.2337/db13-0710
– volume: 306
  start-page: R490
  year: 2014
  ident: 2022031301280987800_B42
  article-title: Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor
  publication-title: Am J Physiol Regul Integr Comp Physiol
  doi: 10.1152/ajpregu.00495.2013
– volume: 20
  start-page: 1645
  year: 2012
  ident: 2022031301280987800_B63
  article-title: Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats
  publication-title: Obesity (Silver Spring)
  doi: 10.1038/oby.2012.59
– volume: 11
  start-page: 1001
  year: 2009
  ident: 2022031301280987800_B26
  article-title: A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2009.01059.x
– volume: 346
  start-page: 393
  year: 2002
  ident: 2022031301280987800_B6
  article-title: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa012512
– volume: 22
  start-page: 5
  year: 2014
  ident: 2022031301280987800_B11
  article-title: Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20662
– volume: 383
  start-page: 1068
  year: 2014
  ident: 2022031301280987800_B105
  article-title: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62154-6
– volume: 22
  start-page: 612
  year: 2005
  ident: 2022031301280987800_B70
  article-title: A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin
  publication-title: Diabet Med
  doi: 10.1111/j.1464-5491.2004.01474.x
– volume: 35
  start-page: 4
  year: 2012
  ident: 2022031301280987800_B44
  article-title: Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc11-0931
– volume: 30
  start-page: 204
  year: 2014
  ident: 2022031301280987800_B56
  article-title: Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
  publication-title: Diabetes Metab Res Rev
  doi: 10.1002/dmrr.2479
– volume: 169
  start-page: 1619
  year: 2009
  ident: 2022031301280987800_B10
  article-title: A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study
  publication-title: Arch Intern Med
  doi: 10.1001/archinternmed.2009.266
– volume: 22
  start-page: 1042
  year: 2014
  ident: 2022031301280987800_B61
  article-title: Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
  publication-title: Obesity (Silver Spring)
  doi: 10.1002/oby.20663
– volume: 308
  start-page: 1099
  year: 2012
  ident: 2022031301280987800_B90
  article-title: Cardiovascular risk assessment in the development of new drugs for obesity
  publication-title: JAMA
  doi: 10.1001/jama.2012.9931
– volume: 36
  start-page: 4022
  year: 2013
  ident: 2022031301280987800_B73
  article-title: Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc13-0234
– volume: 118
  start-page: 2583
  year: 2008
  ident: 2022031301280987800_B22
  article-title: Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli
  publication-title: J Clin Invest
– volume: 193
  start-page: 97
  year: 1993
  ident: 2022031301280987800_B36
  article-title: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas
  publication-title: Res Exp Med (Berl)
  doi: 10.1007/BF02576216
– volume: 377
  start-page: 1341
  year: 2011
  ident: 2022031301280987800_B80
  article-title: Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60205-5
– volume: 87
  start-page: 2784
  year: 2002
  ident: 2022031301280987800_B35
  article-title: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.87.6.8567
– volume: 75
  start-page: 33
  year: 2015
  ident: 2022031301280987800_B55
  article-title: Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
  publication-title: Drugs
  doi: 10.1007/s40265-014-0337-y
– volume: 170
  start-page: 1566
  year: 2010
  ident: 2022031301280987800_B7
  article-title: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial
  publication-title: Arch Intern Med
– volume: 15
  start-page: 729
  year: 2013
  ident: 2022031301280987800_B111
  article-title: Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12083
– volume: 91
  start-page: 254S
  year: 2010
  ident: 2022031301280987800_B107
  article-title: Fibroblast growth factor 21: from pharmacology to physiology
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2009.28449B
– volume: 81
  start-page: 327
  year: 1996
  ident: 2022031301280987800_B39
  article-title: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
  publication-title: J Clin Endocrinol Metab
– volume: 1266
  start-page: 101
  year: 1995
  ident: 2022031301280987800_B30
  article-title: Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0167-4889(94)00237-9
– volume: 9
  start-page: 467
  year: 2013
  ident: 2022031301280987800_B78
  article-title: New pharmacological approaches for obesity management
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2013.113
– volume: 33
  start-page: 169
  year: 2007
  ident: 2022031301280987800_B16
  article-title: Abnormal glucose metabolism in patients treated with antipsychotics
  publication-title: Diabetes Metab
  doi: 10.1016/j.diabet.2007.01.003
– volume: 50
  start-page: 943
  year: 2013
  ident: 2022031301280987800_B49
  article-title: Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients
  publication-title: Acta Diabetol
  doi: 10.1007/s00592-013-0489-3
– volume: 43
  start-page: 249
  year: 2011
  ident: 2022031301280987800_B86
  article-title: Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’
  publication-title: Ann Med
  doi: 10.3109/07853890.2010.541490
– volume: 50
  start-page: 105
  year: 2001
  ident: 2022031301280987800_B28
  article-title: Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract
  publication-title: Diabetes
  doi: 10.2337/diabetes.50.1.105
– volume: 351
  start-page: 1106
  year: 2004
  ident: 2022031301280987800_B33
  article-title: Thiazolidinediones
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra041001
– ident: 2022031301280987800_B103
– volume: 20
  start-page: 87
  year: 2013
  ident: 2022031301280987800_B53
  article-title: GLP-1R agonist therapy for diabetes: benefits and potential risks
  publication-title: Curr Opin Endocrinol Diabetes Obes
  doi: 10.1097/MED.0b013e32835edb32
– volume: 28
  start-page: 1399
  year: 2004
  ident: 2022031301280987800_B81
  article-title: A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
  publication-title: Int J Obes Relat Metab Disord
  doi: 10.1038/sj.ijo.0802783
– volume: 96
  start-page: 243
  year: 2005
  ident: 2022031301280987800_B83
  article-title: Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2005.03.053
– volume: 28
  start-page: 1526
  year: 2005
  ident: 2022031301280987800_B12
  article-title: Weight loss in type 2 diabetic patients
  publication-title: Diabetes Care
  doi: 10.2337/diacare.28.6.1526
– volume: 37
  start-page: 1480
  year: 2014
  ident: 2022031301280987800_B65
  article-title: Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial
  publication-title: Diabetes Care
  doi: 10.2337/dc13-2338
– volume: 11
  start-page: 567
  year: 1988
  ident: 2022031301280987800_B18
  article-title: Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial
  publication-title: Diabetes Care
  doi: 10.2337/diacare.11.7.567
– volume: 15
  start-page: 372
  year: 2013
  ident: 2022031301280987800_B59
  article-title: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12054
– volume: 62
  start-page: 173
  year: 2005
  ident: 2022031301280987800_B41
  article-title: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
  publication-title: Am J Health Syst Pharm
  doi: 10.1093/ajhp/62.2.173
– volume: 36
  start-page: 2497
  year: 2013
  ident: 2022031301280987800_B96
  article-title: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
  publication-title: Diabetes Care
  doi: 10.2337/dc12-2462
– volume: 36
  start-page: 2162
  year: 2013
  ident: 2022031301280987800_B14
  article-title: Determinants of weight gain in the action to control cardiovascular risk in diabetes trial
  publication-title: Diabetes Care
  doi: 10.2337/dc12-1391
– volume: 17
  start-page: 455
  year: 2007
  ident: 2022031301280987800_B17
  article-title: Diet and exercise intervention in a general population—mediators of participation and adherence: the Inter99 study
  publication-title: Eur J Public Health
  doi: 10.1093/eurpub/ckl262
– volume: 11
  start-page: 1677
  year: 2011
  ident: 2022031301280987800_B101
  article-title: Novel strategy for the use of leptin for obesity therapy
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2011.619974
– volume: 37
  start-page: 1544
  year: 2014
  ident: 2022031301280987800_B9
  article-title: Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial
  publication-title: Diabetes Care
  doi: 10.2337/dc13-1928
– volume: 37
  start-page: 187
  year: 2012
  ident: 2022031301280987800_B75
  article-title: Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes
  publication-title: J Clin Pharm Ther
  doi: 10.1111/j.1365-2710.2011.01280.x
– volume: 64
  start-page: 267
  year: 2010
  ident: 2022031301280987800_B50
  article-title: Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2009.02265.x
– volume: 30
  start-page: 1127
  year: 2007
  ident: 2022031301280987800_B32
  article-title: Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
  publication-title: Drug Saf
  doi: 10.2165/00002018-200730120-00005
– volume: 11
  start-page: 26
  year: 2009
  ident: 2022031301280987800_B51
  article-title: The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2009.01075.x
– volume: 15
  start-page: 609
  year: 2014
  ident: 2022031301280987800_B93
  article-title: Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201015666140915150312
– volume: 154
  start-page: 103
  year: 2011
  ident: 2022031301280987800_B94
  article-title: Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-154-2-201101180-00300
– volume: 9
  start-page: 88
  year: 2009
  ident: 2022031301280987800_B4
  article-title: The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-9-88
– volume: 374
  start-page: 39
  year: 2009
  ident: 2022031301280987800_B48
  article-title: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60659-0
– volume: 370
  start-page: 794
  year: 2014
  ident: 2022031301280987800_B54
  article-title: Pancreatic safety of incretin-based drugs—FDA and EMA assessment
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1314078
– volume: 62
  start-page: A16
  year: 2013
  ident: 2022031301280987800_B95
  article-title: IDegLira, a novel fixed ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomized phase 3 trial
  publication-title: Diabetes
– volume: 13
  start-page: 58
  year: 2013
  ident: 2022031301280987800_B66
  article-title: Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
  publication-title: BMC Endocr Disord
  doi: 10.1186/1472-6823-13-58
– volume: 14
  start-page: 464
  year: 2012
  ident: 2022031301280987800_B24
  article-title: Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2012.01556.x
– volume: 7
  start-page: 611
  year: 2012
  ident: 2022031301280987800_B46
  article-title: Efficacy and safety of exenatide once weekly: an overview of the DURATION trials
  publication-title: Expert Rev Endocrinol Metab
  doi: 10.1586/eem.12.51
– volume: 282
  start-page: 503
  year: 1979
  ident: 2022031301280987800_B27
  article-title: Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons
  publication-title: Nature
  doi: 10.1038/282503a0
– volume: 51
  start-page: 134
  year: 2007
  ident: 2022031301280987800_B21
  article-title: Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects
  publication-title: Ann Nutr Metab
  doi: 10.1159/000103273
– volume: 301
  start-page: R581
  year: 2011
  ident: 2022031301280987800_B19
  article-title: Biology’s response to dieting: the impetus for weight regain
  publication-title: Am J Physiol Regul Integr Comp Physiol
  doi: 10.1152/ajpregu.00755.2010
– volume: 126
  start-page: 16
  year: 2014
  ident: 2022031301280987800_B62
  article-title: Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results
  publication-title: Postgrad Med
  doi: 10.3810/pgm.2014.05.2753
– volume: 359
  start-page: 824
  year: 2002
  ident: 2022031301280987800_B38
  article-title: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)07952-7
– volume: 2
  start-page: 911
  year: 2014
  ident: 2022031301280987800_B23
  article-title: Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/S2213-8587(14)70004-X
– volume: 82
  start-page: 4037
  year: 1997
  ident: 2022031301280987800_B29
  article-title: Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.82.12.4460
– volume: 66
  start-page: 1021
  year: 2012
  ident: 2022031301280987800_B52
  article-title: Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2012.03006.x
– volume: 11
  start-page: 1163
  year: 2009
  ident: 2022031301280987800_B89
  article-title: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2009.01158.x
– volume: 42
  start-page: 406
  year: 1999
  ident: 2022031301280987800_B31
  article-title: Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus
  publication-title: Diabetologia
  doi: 10.1007/s001250051172
– volume: 374
  start-page: 1606
  year: 2009
  ident: 2022031301280987800_B87
  article-title: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61375-1
– volume: 16
  start-page: 984
  year: 2014
  ident: 2022031301280987800_B67
  article-title: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12307
– volume: 13
  start-page: 169
  year: 2011
  ident: 2022031301280987800_B69
  article-title: The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2010.01337.x
– volume: 19
  start-page: 352
  year: 2012
  ident: 2022031301280987800_B1
  article-title: Bariatric surgery to treat type 2 diabetes: what is the recent evidence
  publication-title: Curr Opin Endocrinol Diabetes Obes
  doi: 10.1097/MED.0b013e328357f0e0
– volume: 34
  start-page: 1481
  year: 2011
  ident: 2022031301280987800_B8
  article-title: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc10-2415
– volume: 11
  start-page: 361
  year: 2009
  ident: 2022031301280987800_B77
  article-title: Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2008.00970.x
– volume: 57
  start-page: S8
  year: 2014
  ident: 2022031301280987800_B64
  article-title: Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition
  publication-title: Diabetologia
– volume: 95
  start-page: 297
  year: 2012
  ident: 2022031301280987800_B84
  article-title: Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.111.024927
– volume: 21
  start-page: 27
  year: 2015
  ident: 2022031301280987800_B104
  article-title: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
  publication-title: Nat Med
  doi: 10.1038/nm.3761
– volume: 97
  start-page: 1020
  year: 2012
  ident: 2022031301280987800_B57
  article-title: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2011-2260
– volume: 5
  start-page: 163
  year: 2011
  ident: 2022031301280987800_B99
  article-title: Novel approaches to the treatment of obesity and type 2 diabetes mellitus: bioactive leptin-related synthetic peptide analogs
  publication-title: Recent Pat Endocr Metab Immune Drug Discov
  doi: 10.2174/187221411797265917
– ident: 2022031301280987800_B91
– volume: 28
  start-page: 1027
  year: 2012
  ident: 2022031301280987800_B15
  article-title: Characterizing and understanding body weight patterns in patients treated with pregabalin
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007995.2012.684044
– volume: 365
  start-page: 1597
  year: 2011
  ident: 2022031301280987800_B20
  article-title: Long-term persistence of hormonal adaptations to weight loss
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1105816
– volume: 33
  start-page: 1173
  year: 2010
  ident: 2022031301280987800_B92
  article-title: Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes
  publication-title: Diabetes Care
  doi: 10.2337/dc09-1203
– volume: 5
  start-page: 621
  year: 2012
  ident: 2022031301280987800_B74
  article-title: Anti-obesity drugs: past, present and future
  publication-title: Dis Model Mech
  doi: 10.1242/dmm.009621
– volume: 16
  start-page: 159
  year: 2014
  ident: 2022031301280987800_B58
  article-title: Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12189
– ident: 2022031301280987800_B85
– volume: 27
  start-page: 155
  year: 2004
  ident: 2022031301280987800_B76
  article-title: XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients
  publication-title: Diabetes Care
  doi: 10.2337/diacare.27.1.155
– volume: 30
  start-page: 163
  year: 2014
  ident: 2022031301280987800_B60
  article-title: Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007995.2013.850066
– volume: 63
  start-page: 1422
  year: 2014
  ident: 2022031301280987800_B102
  article-title: GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet
  publication-title: Diabetes
  doi: 10.2337/db13-1609
– volume: 5
  start-page: 749
  year: 2009
  ident: 2022031301280987800_B109
  article-title: A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.209
– volume: 363
  start-page: 245
  year: 2010
  ident: 2022031301280987800_B79
  article-title: Multicenter, placebo-controlled trial of lorcaserin for weight management
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0909809
– volume: 12
  start-page: 1439
  year: 2011
  ident: 2022031301280987800_B68
  article-title: Pramlintide and the treatment of diabetes: a review of the data since its introduction
  publication-title: Expert Opin Pharmacother
  doi: 10.1517/14656566.2011.581663
– volume: 20
  start-page: 1426
  year: 2012
  ident: 2022031301280987800_B71
  article-title: Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study
  publication-title: Obesity (Silver Spring)
  doi: 10.1038/oby.2012.66
– volume: 9
  start-page: 799
  year: 2007
  ident: 2022031301280987800_B25
  article-title: Insulin-associated weight gain in diabetes—causes, effects and coping strategies
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2006.00686.x
– volume: 36
  start-page: 843
  year: 2012
  ident: 2022031301280987800_B88
  article-title: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
  publication-title: Int J Obes (Lond)
  doi: 10.1038/ijo.2011.158
– volume: 352
  start-page: 837
  year: 1998
  ident: 2022031301280987800_B13
  article-title: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)07019-6
– volume: 30
  start-page: 1480
  year: 2007
  ident: 2022031301280987800_B82
  article-title: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
  publication-title: Diabetes Care
  doi: 10.2337/dc06-2001
– volume: 15
  start-page: 607
  year: 2013
  ident: 2022031301280987800_B97
  article-title: Leptin therapy in type 2 diabetes
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.12048
– volume: 55
  start-page: 215
  year: 2012
  ident: 2022031301280987800_B100
  article-title: Amylin and leptin activate overlapping signalling pathways in an additive manner in mouse GT1-7 hypothalamic, C2C12 muscle and AML12 liver cell lines
  publication-title: Diabetologia
  doi: 10.1007/s00125-011-2332-0
– ident: 2022031301280987800_B45
– volume: 5
  start-page: 262
  year: 2009
  ident: 2022031301280987800_B98
  article-title: Incretin-based therapies for type 2 diabetes mellitus
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/nrendo.2009.48
– volume: 27
  start-page: 1519
  year: 2011
  ident: 2022031301280987800_B43
  article-title: GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
  publication-title: Curr Med Res Opin
  doi: 10.1185/03007995.2011.590127
– volume: 444
  start-page: 875
  year: 2006
  ident: 2022031301280987800_B2
  article-title: Mechanisms linking obesity with cardiovascular disease
  publication-title: Nature
  doi: 10.1038/nature05487
– volume: 56
  start-page: 841
  year: 2008
  ident: 2022031301280987800_B37
  article-title: Expression of the GLP-1 receptor in mouse, rat, and human pancreas
  publication-title: J Histochem Cytochem
  doi: 10.1369/jhc.2008.951319
– ident: 2022031301280987800_B3
– volume: 37
  start-page: 3309
  year: 2014
  ident: 2022031301280987800_B72
  article-title: Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
  publication-title: Diabetes Care
  doi: 10.2337/dc14-0930
– volume: 15
  start-page: 42
  year: 2013
  ident: 2022031301280987800_B47
  article-title: Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
  publication-title: Diabetes Obes Metab
  doi: 10.1111/j.1463-1326.2012.01673.x
– volume: 60
  start-page: 1272
  year: 2006
  ident: 2022031301280987800_B34
  article-title: Thiazolidinediones, insulin resistance and obesity: finding a balance
  publication-title: Int J Clin Pract
  doi: 10.1111/j.1742-1241.2006.01128.x
RestrictionsOnAccess restricted access
SSID ssj0004488
Score 2.5379667
SecondaryResourceType review_article
Snippet Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are intrinsically linked: obesity increases the risk of diabetes and also...
SourceID liege
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1161
SubjectTerms Anti-Obesity Agents - therapeutic use
Blood Glucose - metabolism
Cardiovascular disease
Diabetes
Diabetes Mellitus, Type 2 - prevention & control
Diabetic Angiopathies - prevention & control
Drug Therapy, Combination
Endocrinologie, métabolisme & nutrition
Endocrinology, metabolism & nutrition
Forecasting
Human health sciences
Humans
Hypoglycemic Agents - adverse effects
Medical treatment
Obesity
Obesity - prevention & control
Pharmacie, pharmacologie & toxicologie
Pharmacy, pharmacology & toxicology
Risk Reduction Behavior
Sciences de la santé humaine
Weight control
Weight Gain - drug effects
Weight Loss - drug effects
Title Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/25998297
https://www.proquest.com/docview/1686813906
https://www.proquest.com/docview/1702644605
http://orbi.ulg.ac.be/handle/2268/182310
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQKyEuiDfbFmQQByQIJLaT2NxWQFnoQzy20JvlxA6ttMqikuXAr2fGzmurgoBLFCWWbc18tmfG8yDkUV5UTrgkjVRpskhUCY-MhOVeMqaKklshDAYKHxxmsyPx7jg9Hqpt-uiSpnhW_rwwruR_uArfgK8YJfsPnO07hQ_wDvyFJ3AYnn_F4y_erjlyYUHrxTwYVVtXF-_x1iVhQiM5WqF8YaJpm0085HiYdw7nY2m168Pnr-5Y8xl2hDfG1wl4sr8qh5uck7bGPfpIhvv3sUkBGNW7Po28-KGzfpTzUOlskSpKlVrbTLkcgWa8MyZJSLp-fstm3Af92zIREciG8XAudXfxs-kn_f7Vrt5_e7i3_jccw3ksQSfKUAfeZKAsYB2LvQ-jnPHCVx_tpxvyS-G4z_tR16SSzQX6K_xe5fCix_waudrqDHQaAHCdXHL1DXL5oPWKuEk-BhzQAQf0tKaIA8poR90XtEUBBRTQDgV0QAFtlrRHwS1ytPt6_nIWtbUyIiNy1US5YUokJjOVKoUtWFVUzOWyxHJwqbG8Yjy3hstKclAoubBpyk2uHLNJbmxq-W2yUS9rd5fQ1GZSGNCjpa1E4ZxyUqaiYMJKOA9MPCGPO1rpsk0kj_VMFhoUSiSrRrJqJOuEPOybfgvZUy5q9NQTXC_PilP9g2nMeO7fV4uv2pS6cBqUBKkTvLKG5jsdX3S7Fr9DPzKToMzE2YQ86H_DTonXX6Z2yxW0yWOU_kF_n5A7gZ_9pBgAA4PMt_7c-Ta5MqyXHbLRnK3cPRBKm-K-x9wvioOK9g
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Weight+Management+in+Type+2+Diabetes%3A+Current+and+Emerging+Approaches+to+Treatment&rft.jtitle=Diabetes+care&rft.au=Van+Gaal%2C+Luc&rft.au=Scheen%2C+Andr%C3%A9&rft.date=2015-06-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.volume=38&rft.issue=6&rft.spage=1161&rft_id=info:doi/10.2337%2Fdc14-1630&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3708747661
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon